Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2024)

Solid Biosciences' Income from Continuing Operations history spans 8 years, with the latest figure at 38046000.0 for Q4 2024.

  • For Q4 2024, Income from Continuing Operations fell 84.64% year-over-year to 38046000.0; the TTM value through Dec 2024 reached 120599000.0, down 24.19%, while the annual FY2024 figure was 120599000.0, 24.19% down from the prior year.
  • Income from Continuing Operations for Q4 2024 was 38046000.0 at Solid Biosciences, down from 32936000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 16900000.0 in Q1 2021 and bottomed at 38046000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 22834500.0 (2020), against an average of 24105850.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 37.62% in 2023 before it tumbled 84.64% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 21363000.0 in 2020, then rose by 12.69% to 18652000.0 in 2021, then plummeted by 77.1% to 33032000.0 in 2022, then surged by 37.62% to 20606000.0 in 2023, then crashed by 84.64% to 38046000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Income from Continuing Operations are 38046000.0 (Q4 2024), 32936000.0 (Q3 2024), and 25311000.0 (Q2 2024).